Experimental drug combo targets tough blood cancers

NCT ID NCT01905813

Completed Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new drug called INCB040093, alone or combined with itacitinib, in 121 adults with B-cell cancers that had come back or stopped responding to treatment. The main goal was to find safe doses and check for side effects. Researchers also looked for signs that the drugs might shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: INCB040093 (a PI3Kδ inhibitor) and itacitinib (a JAK1 inhibitor)
What this could lead to: If it works, this could point toward a new treatment option for people with B-cell cancers that have not responded to prior therapies.
What could go wrong: This is an early Phase 1 trial focused on safety and dosing, not on proving effectiveness. The drug may cause side effects or fail to shrink tumors in later studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia B-cell neoplasm B-cell non-Hodgkin lymphoma hairy cell leukemia Hodgkins lymphoma mantle cell lymphoma non-Hodgkin lymphoma Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL MALIGNANCIES

Contacts and locations

Locations

Study site

Birmingham, Alabama, United States
Study site

Jacksonville, Florida, United States
Study site

Ann Arbor, Michigan, United States
Study site

Rochester, Minnesota, United States
Study site

New York, New York, United States
Study site

Rochester, New York, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.